Viatris is cutting 3,200 employees, 10% of its global workforce, projecting $600-700 million in savings. The generic pharmaceutical company was formed from the merger of Mylan and Pfizer's Upjohn division, and the cuts represent ongoing integration that has been slower than investors expected.
The generic drug business operates on thin margins, and Viatris has been under pressure to demonstrate that the merger created value beyond simply combining two struggling businesses. The $600-700 million savings target is significant, but achieving it by cutting 10% of the workforce raises questions about whether the company can maintain its manufacturing and distribution capabilities.